Ligand Pharma (LGDN) AI Stock Analysis

1 Followers

Ligand Pharma

(Frankfurt:LGDN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Royalty Revenue GrowthStrong royalty growth demonstrates that Ligand’s partnered-asset model is gaining commercial traction. Because royalties can scale with partner product sales without requiring a large direct sales force, continued portfolio performance could support recurring revenue and operating leverage over the next several quarters.

Negative Factors

Declining and Volatile RevenueThe recent topline decline and uneven multi-year profitability indicate that Ligand’s earnings base is not yet consistently durable. Revenue can be affected by licensing events, milestones and partner product performance, making forward earnings less predictable even while current margins remain positive.

Ligand Pharma (LGDN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.34B
Dividend Yield: ―
Average Volume (3M): 27
Price to Earnings (P/E): 122.3
Beta (1Y): 0.43
Revenue Growth: -2.38%
EPS Growth: 29.65%
Country: Germany
Employees: 47
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Ligand Pharma Business Overview & Revenue Model

Company Description

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. It...

Ligand Pharma Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:0.74%|Next Earnings Date:Mar 04, 2027

Earnings Call SentimentPositive

The call was predominantly positive. Royalty revenue grew 51%, adjusted EPS guidance was raised, the XOMA acquisition expanded the commercial and pipeline portfolio, deployable capital remained substantial, and management highlighted multiple upcoming catalysts. Offsetting items included lower reported adjusted EPS versus a prior period with one-time income, a GAAP net loss, higher one-time G&A costs, cash usage for the XOMA acquisition, revenue-timing uncertainty and clinical development risk.

Positive Updates

Royalty Revenue Growth

Third-quarter royalty revenue grew 51% year-over-year to $70.3 million, reflecting the contribution from the XOMA-acquired assets and continued momentum across the legacy portfolio.

Negative Updates

Adjusted EPS Declined Year-over-Year

Adjusted diluted EPS was $2.67 in the third quarter versus $3.09 in the prior-year quarter. The comparison included $24.5 million of one-time Zelsuvmi out-license income in the prior year, which was absent this quarter.

Company Guidance

Ligand reaffirmed full year 2026 revenue guidance of royalty revenue of $225 million to $250 million, total revenue of $270 million to $310 million, Captisol revenue of $35 million to $40 million and contract revenue of $10 million to $20 million, while raising adjusted diluted earnings per share guidance to $9.50 to $9.75 per share from $9 to $9.50 per share; 2026 revenue is expected to be weighted more heavily towards the fourth quarter, and management said it has a high level of confidence it will approach the mid- to higher end, if not even exceed it, of the implied Q4 royalty range, with core cash operating expenses remaining on track at approximately $50 million, XOMA contributing $0.50 to earnings in '26 and $1.50 in '27, and incremental XOMA costs expected to be just under $5 million per year; Ligand will update its five-year outlook, which previously targeted a 23% royalty receipt CAGR, on December 8, and expects up to seven pivotal trial readouts through 2027.

Ligand Pharma Risk Analysis

Ligand Pharma disclosed 68 risk factors in its most recent earnings report. Ligand Pharma reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.We may not successfully integrate the business, operations and royalty portfolio acquired in the XOMA Acquisition or realize the anticipated benefits of the acquisition.Q2, 2026

2.Certain of our royalty and milestone arrangements are subject to contractual rights held by our licensees or sublicensees to reduce, buy down, or buy out royalty obligations upon payment of specified amounts, which may be less than the net present value of future royalties we would otherwise be entitled to receive.Q2, 2026

3.Litigation in connection with the XOMA Acquisition.Q2, 2026

Ligand Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:LGDN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABCL	58Neutral	$4.07B	-24.89	-15.35%	―	92.10%	16.43%
ZYME	55Neutral	$2.19B	43.39	22.48%	―	97.78%	―
XNCR	54Neutral	$2.96B	-25.46	-21.29%	―	33.55%	11.51%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARWR	49Neutral	$6.92B	-22.04	-60.54%	―	16.85%	-80.39%
IONS	42Neutral	$4.69B	-8.53	-120.44%	―	-0.79%	-106.48%

* Healthcare Sector Average

Performance Comparison

DE:LGDN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:LGDN	Ligand Pharmaceuticals Inc	274.00	100.00	57.47%
ARWR	Arrowhead Pharmaceuticals, Inc.	49.36	8.22	19.98%
IONS	Ionis Pharmaceuticals Inc.	28.33	-41.51	-59.44%
XNCR	Xencor Inc.	39.97	25.98	185.70%
ZYME	Zymeworks	29.07	10.57	57.14%
ABCL	Abcellera Biologics, Inc.	11.95	8.33	230.11%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ligand Pharma AI Stock Analysis